News | News By Subject | News by Disease News By Date | Search News

Renal Cell Carcinoma News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Exelixis (EXEL)'s Cabozantinib Shines in Late Stage Study for Patients with Advanced RCC     1/6/2016
AVEO Oncology (AVEO), EUSA Pharma Form $396.5 Million Exclusive Licensing Agreement for Tivozanib in Europe     12/21/2015
Bristol-Myers Squibb (BMY) Grabs Breakthrough Tag for Opdivo     9/16/2015
Revitalized Exelixis (EXEL) Grabs Breakthrough Tag for Cabozantinib     8/25/2015
Bristol-Myers Squibb (BMY)'s Opdivo Phase III Study Stopped Early on More Good Cancer Therapy News     7/21/2015
Embattled Exelixis (EXEL) Nabs Much-Needed Victory for Phase III Renal Cell Carcinoma Study     7/21/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Bionomics Limited (BNO.AX) Sinks As Renal Cancer Drug Fails Key Phase 2 Test     3/19/2014
FDA Committee Turns Down AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO)/Astellas Pharma Inc. (YPH.BE)'s Cancer Drug     5/6/2013
Pfizer Inc. (PFE) Kidney Cancer Drug Fails as Initial Treatment     10/18/2012
Pfizer Inc. (PFE)'s Torisel Drug Fails in a Combination Study     8/13/2012
Pfizer Inc. (PFE)'s Torisel Fails Phase III Renal Cell Carcinoma Study in Showdown Against Bayer HealthCare (BAY)'s Nexavar     5/16/2012
Argos Therapeutics, Inc. Raises $25 Million Series D Financing     4/24/2012
AVEO Pharmaceuticals, Inc. (AVEO) Announces Publication of Positive Tivozanib Phase 2 Clinical Trial Results in Journal of Clinical Oncology     4/12/2012

News from Around the Web

Press Releases
Exelixis (EXEL) Announces FDA Deems New Drug Application Sufficiently Complete And Grants Priority Review For Cabozantinib As A Treatment For Advanced Renal Cell Carcinoma     1/28/2016
Eisai Inc. (ESALF.PK)'s Lenvatinib Receives FDA Priority Review For The Potential Treatment Of Advanced Renal Cell Carcinoma In Combination With Everolimus     1/18/2016
Exelixis (EXEL) Submits Marketing Authorization Application In The European Union For Cabozantinib As A Treatment For Advanced Renal Cell Carcinoma     1/11/2016
Cancer Genetics (CGIX) To Present Results Of Collaborative Renal Biopsy And Clear Cell Renal Cell Carcinoma (Ccrcc) Studies At The 2016 Genitourinary Cancer Symposium     1/7/2016
Argos Therapeutics, Inc. (ARGS) Release: Independent Data Monitoring Committee Recommends Continuation Of ADAPT Phase III Clinical Trial Of AGS-003 For Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis     12/10/2015
Celldex (CLDX) Initiates Phase I/II Study Of Varlilumab In Combination With Atezolizumab In Renal Cell Carcinoma     12/8/2015
AVEO Oncology (AVEO) Reports Third Quarter 2015 Financial Results And Provides Business Update     11/9/2015
Cancer Genetics (CGIX) To Report Biomarker Findings In Metastatic Clear Cell Renal Carcinoma Using A CGI-Designed NGS Panel At The 14th International Kidney Cancer Symposium In Miami, FL     11/9/2015
Eisai Inc. (ESALF.PK) Release: Results From Phase 2 Trial Investigating Lenvatinib In Metastatic Renal Cell Carcinoma Published In The Lancet Oncology     10/16/2015
Cerulean Pharma Inc. (CERU) Announces Completion Of Enrollment Of Randomized Phase II Trial Of CRLX101 In Combination With Avastin In Relapsed Renal Cell Carcinoma     10/15/2015
Exelixis (EXEL) Announces Positive Results From METEOR Phase 3 Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma Presented At European Cancer Congress 2015     9/28/2015
Bristol-Myers Squibb (BMY) Release: Opdivo (nivolumab) Demonstrates Superior Overall Survival In A Phase 3 Trial Compared To Standard Of Care In Patients With Previously Treated Advanced Renal Cell Carcinoma     9/28/2015
Exelixis (EXEL) Release: Data From METEOR Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma Accepted As Late-Breaker Presentation In Presidential Session At European Cancer Congress 2015     8/24/2015
Argos Therapeutics, Inc. (ARGS) Reports Second Quarter 2015 Financial Results And Operational Highlights     8/13/2015
Argos Therapeutics, Inc. (ARGS) Announces Pilot Clinical Trial Of AGS-003 As Neoadjuvant Immunotherapy For Localized Renal Cell Carcinoma     8/10/2015